XTalks

AUGUST 21, 2023

Other Promising Treatments for FOP This endorsement places Ipsen in a leading position compared to other pharma companies like Regeneron Pharmaceuticals, which is also working on an investigational drug, garetosmab, for the same condition and anticipates submitting an application for approval to the FDA in 2024.

Drugs 98

Drugs FDA Approval Genetics Clinical Trials 98

pharmaphorum

AUGUST 25, 2021

Remdesivir was the first antiviral drug to receive conditional marketing authorisation in the UK by its producer, Gilead Sciences. It’s now globally accessible due to Gilead’s work with a network of generic manufacturers and their ability to sign licensing agreements just days after the US FDA registered its authorisation.

Marketing 52

Marketing Licensing Licensing Manufacturing 52

XTalks

SEPTEMBER 5, 2023

Investigation of the possibility of VAED is crucial during clinical trials for decision-making on vaccine licensing by regulatory agencies. To address cultural considerations, it is essential that pharma companies work together with healthcare providers to promote trust in vaccines.

Vaccination 96

Vaccination Vaccine Development Clinical Trials 96

pharmaphorum

APRIL 19, 2022

In 2022, pharma is truly a global industry, and innovation can come from anywhere. But for small life sciences outside of the USA and Europe, it can still be challenging to break onto this global stage. The company recently raised $16.5 The company’s second drug candidate, RCI002, is focused on chronic pain.

Marketing 52

Marketing Clinical Trials Clinical Trials Development 52

XTalks

DECEMBER 29, 2022

The life sciences and healthcare are among the biggest industries globally, and their significance was particularly highlighted during the past couple of years by the COVID-19 pandemic. Given the hyperfocus on the life sciences thanks to COVID, consumers appear to be more autonomous and vocal about their medical demands and choices.

Life Science 52

Life Science Gene Therapy Gene Manufacturing 52

pharmaphorum

SEPTEMBER 18, 2020

But although it was dubbed a “dangerous game”, some companies came out on top… On 6th April 1999, two companies with similar science-based cultures and a shared vision of the pharmaceutical industry came together to form what’s now considered as one of the top ten pharma companies in the world: AstraZeneca.

Pharma Companies 116

Pharma Companies Sales Vaccine Vaccination 116

XTalks

DECEMBER 13, 2023

Now, let’s delve into the list of the top ten fastest growing biotech companies in 2023, ranked by their compound annual growth rate (CAGR). These companies were identified through The Americas’ Fastest-Growing Companies 2023 list by the Financial Times. million, compared to $1.1 million for the same period in 2022.

Genetics 111

Genetics Vaccine Vaccination DNA 111

Pharma Business Blog

MARCH 16, 2022

Happy to share the following Article of Chemie Pharma Innovation with you (German only): [link]. Dr. Sandra Ragaz , Partner Leader Pharma & Life Science VAT Switzerland Tel: +41 58 792 44 69 sandra.ragaz@pwc.ch. Der Beitrag The Pharma Gamechanger erschien zuerst auf Welcome. Have a pleasant reading.

Life Science 52

Life Science Licensing Licensing Pharma Companies 52

XTalks

MAY 29, 2024

The top ten pharma companies in 2023 by revenue accounted for about 35 percent of the market value, with total earnings of $559.5 The top big pharma players have remained relatively consistent in their market positions over the past several years. Here is a look at the top ten pharma companies in 2024 based on 2023 revenue.

Pharma Companies 52

Pharma Companies Sales FDA Approval Vaccine 52

pharmaphorum

MARCH 26, 2021

The UK Government and EU Commission trumpeted their Brexit trade deal, struck at the end of December, as ‘comprehensive’, the ‘biggest yet’ But a closer inspection of the EU-UK Trade and Cooperation Agreement (TCA) renders these statements largely illusory for the pharma sector. Andrew is also an expert on GDPR.

Production 119

Production Medicine Marketing Regulation 119

pharmaphorum

MAY 27, 2022

There is a huge opportunity for pharma companies to capitalise on by focusing on increased DEI in clinical trials. Underrepresentation is multifactorial, so concerted efforts from life science companies are required to address inequitable healthcare. What comes next?

Clinical Trials 80

Clinical Trials Clinical Trials Trials Packaging 80

pharmaphorum

MAY 14, 2021

“NICE is still considered to offer a transparent and clear methodological framework for regulators and companies, and so whilst the intricacies of working in a post-Brexit world are ironed out it would seem unlikely that pharma companies/regulators would move away from continuing to engage with NICE.”.

Marketing 59

Marketing Regulation Medicine Life Science 59

Pharmaceutical Technology

JANUARY 25, 2023

“We had over 100 companies go public in the sector in 2020 and 2021. Many of those companies were uncharacteristically early in development,” notes Barbara Ryan, senior advisor of Life Sciences at Ernst & Young. Quoting EY’s annual Firepower Report , Ryan says pharma companies hold $1.4

Marketing 173

Marketing Life Science Pharma Companies Licensing 173

Pharmaceutical Technology

MAY 26, 2023

After raising $125m in 2021 to redevelop the facility, more recently Touchlight secured an additional $17.3m (£14m) from the UK government’s Life Sciences Innovative Manufacturing Fund to accelerate its expansion plans and scale-up equipment.

DNA 130

DNA Manufacturing Gene Gene Therapy 130

Roots Analysis

JANUARY 27, 2025

Such deals are inked to allow companies to expand their respective technology / product portfolios, and gain additional capabilities related to subcutaneous biologics. Notably, technology licensing agreements emerged as the most popular type of partnership model adopted by stakeholders in the subcutaneous biologics market.

Marketing 40

Marketing Drug Delivery Development Protein 40

XTalks

FEBRUARY 15, 2024

US Senator Bernie Sanders, who chairs the Health, Education, Labor, and Pensions (HELP) Committee, managed to bring CEOs of major American pharma companies to a committee hearing to discuss exorbitant US drug pricing.

Drugs 52

Drugs Pharma Companies Pharmacy Medicine 52